Phase 3 Clinical Trials With Primary Completion Dates in June 2024

This is a list of Phase 3 trials with primary completion dates in June 2024 for companies with a market cap less than $1B. For complete clinical trial coverage, please see our Trial Tracker tool. It includes information on all clinical trials for publicly traded companies, screenable by stock symbol, market cap, disease, completion date, and phase.

The primary completion date is the date that the final subject was examined or received an intervention for the purposes of final collection of data for the primary outcome. It provides advance notice that a company will be announcing trial results in the near future.

Symbol Company Primary Completion Date Phase NCT ID Title
AEZS Aeterna Zentaris Inc. 2024-06-01 Phase 3 NCT04786873 A Research Study of How Well Macimorelin Works to Find Out if Children Have a Lack of Growth Hormone and How Safe it is
AGIO Agios Pharmaceuticals, Inc. 2024-06-01 Phase 3 NCT03853798 Extension Study of AG-348 in Adult Participants With Pyruvate Kinase Deficiency Previously Enrolled in AG-348-006 or AG348-C-007
ANAB AnaptysBio, Inc. 2024-06-01 Phase 3 NCT05366855 Long-Term Safety and Efficacy of Imsidolimab (ANB019) in Subjects With Generalized Pustular Psoriasis
APLS Apellis Pharmaceuticals, Inc. 2024-06-01 Phase 3 NCT05067127 Phase III Study Assessing the Efficacy and Safety of Pegcetacoplan in Patients With C3 Glomerulopathy or Immune-Complex Membranoproliferative Glomerulonephritis
CORT Corcept Therapeutics Incorporated 2024-06-01 Phase 3 NCT05257408 Relacorilant in Combination With Nab-Paclitaxel in Advanced, Platinum-Resistant, High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian-Tube Cancer
EIGR Eiger BioPharmaceuticals, Inc. 2024-06-01 Phase 3 NCT04727424 Repurposed Approved and Under Development Therapies for Patients With Early-Onset COVID-19 and Mild Symptoms
GLYC GlycoMimetics, Inc. 2024-06-01 Phase 3 NCT03616470 Study to Determine the Efficacy of Uproleselan (GMI-1271) in Combination With Chemotherapy to Treat Relapsed/Refractory Acute Myeloid Leukemia
HLBBF H. Lundbeck A/S 2024-06-01 Phase 3 NCT05064371 Long-Term Extension Study With Eptinezumab as Preventive Treatment in Participants With Migraine in Japan
MIST Milestone Pharmaceuticals Inc. 2024-06-01 Phase 3 NCT05410860 Efficacy and Safety Study of Etripamil Nasal Spray Self-Administration for the Termination of Spontaneous Episodes of Paroxysmal Supraventricular Tachycardia
PALI Palisade Bio, Inc. 2024-06-01 Phase 3 NCT05470387 A Study to Evaluate LB1148 for Return of Bowel Function in Subjects Undergoing Bowel Resection
RLMD Relmada Therapeutics, Inc. 2024-06-01 Phase 3 NCT04855747 A Study to Assess the Efficacy and Safety of REL-1017 as Adjunctive Treatment for Major Depressive Disorder (MDD)
SCYX SCYNEXIS, Inc. 2024-06-01 Phase 3 NCT05178862 A Phase 3, Randomized, Double-blind Study for Patients With Invasive Candidiasis Treated With IV Echinocandin Followed by Either Oral Ibrexafungerp or Oral Fluconazole
SVRA Savara Inc. 2024-06-01 Phase 3 NCT04544293 Clinical Trial of Inhaled Molgramostim Nebulizer Solution in Autoimmune Pulmonary Alveolar Proteinosis (aPAP)